NBIX · NASDAQ
Neurocrine Biosciences (NBIX) Stock Price & Fundamentals
Neurocrine Biosciences (NBIX) closed at $444.56 on Oct 9, 2026, down 0.85% from the previous close of $448.38.
Share price, past year
1Y −6.17%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $444.56 |
| Sep 30, 2026 | $456.78 |
| Aug 31, 2026 | $450.12 |
| Jul 31, 2026 | $445.45 |
| Jun 30, 2026 | $435.62 |
| May 29, 2026 | $438.75 |
| Apr 30, 2026 | $469.99 |
| Mar 31, 2026 | $480.38 |
| Feb 27, 2026 | $479.02 |
| Jan 30, 2026 | $479.49 |
| Dec 31, 2025 | $492.43 |
| Nov 28, 2025 | $470.87 |
| Oct 31, 2025 | $468.08 |
Key statistics
- Market cap
- $45.17B
- P/E (TTM)
- 65.1
- EPS (TTM)
- $6.83
- Revenue (TTM)
- $3.37B
- Net income (TTM)
- $705.50M
- Shares outstanding
- 101.6M
- Dividend yield
- —
- 52-week range
- $427.45 – $518.02
Neurocrine Biosciences's market cap is $45.17B, based on a share price of $444.56 and 101.6M shares outstanding as of Jun 30, 2026.
Financials
Neurocrine Biosciences reported revenue of $2.86B for fiscal 2025, up 21.45% from fiscal 2024.
Neurocrine Biosciences earned net income of $478.60M in fiscal 2025, a net margin of 16.7%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $2.86B | +21.5% | $478.60M | 16.7% | $4.67 | $748.70M |
| FY2024ended Dec 31, 2024 | $2.36B | +24.8% | $341.30M | 14.5% | $3.29 | $557.20M |
| FY2023ended Dec 31, 2023 | $1.89B | +26.8% | $249.70M | 13.2% | $2.47 | $361.60M |
| FY2022ended Dec 31, 2022 | $1.49B | +31.3% | $154.50M | 10.4% | $1.56 | $322.90M |
| FY2021ended Dec 31, 2021 | $1.13B | +8.4% | $89.60M | 7.9% | $0.92 | $233.10M |
| FY2020ended Dec 31, 2020 | $1.05B | +32.7% | $407.30M | 38.9% | $4.16 | $217.60M |
| FY2019ended Dec 31, 2019 | $788.10M | +74.7% | $37.00M | 4.7% | $0.39 | $132.30M |
| FY2018ended Dec 31, 2018 | $451.20M | +179.2% | $21.10M | 4.7% | $0.22 | $76.60M |
| FY2017ended Dec 31, 2017 | $161.63M | +977.5% | −$142.54M | −88.2% | −$1.62 | −$101.27M |
| FY2016ended Dec 31, 2016 | $15.00M | — | −$141.09M | −940.6% | −$1.63 | −$110.29M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $959.00M | $144.40M | $1.39 |
| Q1 FY2026ended Mar 31, 2026 | $814.50M | $197.90M | $1.91 |
| Q4 FY2025ended Dec 31, 2025 | $805.50M | $153.70M | $1.49 |
| Q3 FY2025ended Sep 30, 2025 | $794.90M | $209.50M | $2.04 |
| Q2 FY2025ended Jun 30, 2025 | $687.50M | $107.50M | $1.06 |
| Q1 FY2025ended Mar 31, 2025 | $572.60M | $7.90M | $0.08 |
| Q4 FY2024ended Dec 31, 2024 | $627.70M | $103.10M | $1.00 |
| Q3 FY2024ended Sep 30, 2024 | $622.10M | $129.80M | $1.24 |
Company profile
- Name
- Neurocrine Biosciences, Inc.
- Ticker
- NBIX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 6027 Edgewood Bend Court, San Diego, CA 92130
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000914475
Recent SEC filings
- Sep 28, 2026
- Jul 31, 2026
- Jul 30, 2026
- May 28, 2026
- May 18, 2026
- May 5, 2026
- May 5, 2026
- Apr 6, 2026
Frequently asked questions
What is Neurocrine Biosciences's stock price?
Neurocrine Biosciences (NBIX) closed at $444.56 on Oct 9, 2026, down 0.85% from the previous close of $448.38.
What is Neurocrine Biosciences's market cap?
Neurocrine Biosciences's market cap is $45.17B, based on a share price of $444.56 and 101.6M shares outstanding as of Jun 30, 2026.
How much revenue does Neurocrine Biosciences make?
Neurocrine Biosciences reported revenue of $2.86B for fiscal 2025, up 21.45% from fiscal 2024.
What is NBIX's P/E ratio?
Neurocrine Biosciences's price-to-earnings ratio is 65.1, based on trailing twelve-month diluted EPS of $6.83.
Does Neurocrine Biosciences pay a dividend?
Neurocrine Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Neurocrine Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures